Glycopolymers for solid brain tumour drug delivery

Evelyn Szabo,^{a,c} David Ziegler^a, Maria Tsoli,^a Giuseppe Mantovani^b, <u>Martina H. Stenzel</u>^c

^a Children's Cancer Institute, Randwick, Sydney, NSW, Australia ^b The University of Nottingham, Nottingham, United Kingdom ^c The University of New South Wales, Kensington, Sydney, NSW, Australia

Email: M.Stenzel@unsw.edu.au

A plethora of cancers show increased glucose uptake and thus overexpression of GLUT receptors because of dysfunctional metabolism known as the Warburg effect. This observation laid the foundation for monosaccharide conjugated analogues, which demonstrate improved pharmacodynamics and kinetics¹ but fail to protect the drug from enzymatic degradation and to deliver hydrophobic drugs to cancers locked behind a very tightly regulated border, such as the blood brain barrier. ^{3,4} A way to combat this is using a system that can act as a reservoir for drugs, while also showing selective delivery, such as glycopolymeric nanoparticles. However, while there is some study on structural requirement of monosaccharide-conjugates for binding to the glucose transport system,^{2,5} it remains largely unexplored, and in the case of a bulkier systems, such as glycopolymers, the requirements for binding to the sugar transport system are yet to be identified. This study aimed to examine the effect of glucose based glycopolymers of different glucose analogues (C1, C2, C6 conjugated sugars) in in vitro models. Their binding affinity and specificity were evaluated by flow cytometry against several healthy and cancer cell lines. Results indicated similar report and structural requirement for binding to that of studies completed on glucose molecules, paving the way to a promising drug delivery system.^{2,5}

References

- 1. Calvaresi, E. C.; Hergenrother, P. J. Glucose Conjugation for the Specific Targeting and Treatment of Cancer. Chem. Sci. R. Soc. Chem. 2010 2013, 4 (6), 2319–2333. https://doi.org/10.1039/C3SC22205E.
- 2. Barnett, J.E. Holman, G.D. Munday, K.A. Structural requirements for binding to the sugar-transport system of the human erythrocyte. Biochem J.1973. 131(2), 211-21. https://doi.10.1042/bj1310211.
- Haumann, R.; Videira, J. C.; Kaspers, G. J. L.; van Vuurden, D. G.; Hulleman, E. Overview of Current Drug Delivery Methods Across the Blood–Brain Barrier for the Treatment of Primary Brain Tumors. CNS Drugs 2020, 34 (11), 1121–1131. https://doi.org/10.1007/s40263-020-00766-w
- Jiang, X., Xin, H. Ren, Q. Gu, J. Zhu, L. Du, F. Feng, C. Xie, Y. Sha, X. Fang, X. Nanoparticles of 2-deoxy-d-glucose functionalized poly(ethylene glycol)-co-poly(trimethylene carbonate) for dual-targeted drug delivery in glioma treatment. Biomaterials. 2014. 35 (1), 518-529. https://doi.org/10.1016/j.biomaterials.2013.09.094.
- 5. Lloyd, K. Understanding Human Erythrocyte Glucose Transporter (GLUT1) Mediated Glucose Transport Phenomena Through Structural Analysis. 2018. https://doi.org/10.13028/M2DH4J.